Participants 250 297 7
in patients with obstructive sleep apnea (OSA).
Participants 508 578 4
Patients were admitted to the laboratory for three consecutive nights.
Participants 784 886 3
patients received 200 mg modafinil or placebo (n = 21) in a randomized, double-blind, crossover design
Participants 1554 1744 3
CONCLUSIONS Modafinil prevented the decline in simulated driving performance, neurocognitive performance, and subjective sleepiness in patients with OSA with acutely interrupted CPAP therapy
